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Background. Serum concentration of NT-proBNP correlates well with the severity of cardiac disease in adults. Few studies have
been performed on the applicability of NT-proBNP for monitoring children with congenital heart disease. Objective. To assess
the potential of NT-proBNP for monitoring the success of interventions in children with stenotic cardiac lesions. Methods. NT-
proBNP was measured in 42 children aged 1 day to 17 years (y) before and 6 to 12 weeks after surgical or interventional correction
of obstructive lesions of the heart. Comparison is made with the clinical status and echocardiographic data of the child. Results.
NT-proBNP levels (median 280, range 10–263,000pg/mL) were above the reference value in all but 6 patients (pts) prior to
the intervention. Higher levels were found in more compromised patients. The 35 children with clinical improvement after the
procedure showed a decline of their NT-proBNP level in all but 4 patients, whose levels remained unchanged. Five patients with
unchanged gradients despite a therapeutic intervention also demonstrated unchanged NT-proBNP levels after the intervention.
Thus, the success rate of the procedure correlated well to clinical and echocardiographic ﬁndings. Conclusion. NT-proBNP can be
used to assess the eﬃciency of an intervention.
Copyright © 2009 Eva Welisch et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
Natriuretic hormones are released by the myocardium
secondary to an increased wall tension caused by volume
or pressure in order to protect the cardiovascular system.
They are well-established markers for diagnosis, prognosis,
and risk stratiﬁcation in adult patients with congestive
heart failure. They are easy to measure, provide a useful
tool for monitoring therapeutic success, and are evolving
as an important prognostic parameter [1–7]. Their release
is triggered by norepinephrine, endothelin 1, vasopressin,
and arginine. BNP is formed after enzymatic cleavage of
pre-proBNP in the active form of BNP and the inactive
aminoterminal fragment NT-proBNP. BNP causes vasodi-
lation, natriuresis, and diuresis by inhibiting the release of
renin. The dilatation of the vessels is caused by reduced
formation of angiotensin II, whereas the diuretic eﬀect is
related to a decreased formation of aldosterone. NT-proBNP
also modulates the activity of the sympathicoadrenal system
by inhibition of the release of endothelin and is known to
have antimitogenic properties [8, 9].
While NT-proBNP closely correlates with BNP levels,
NT-proBNP exhibits greater stability and thus may serve
as a preferred marker to assess cardiac stress. The potential
advantages of NT-proBNP, especially for paediatric patients,
have been described in detail elsewhere [8].2 International Journal of Pediatrics
Table 1: Underlying cardiac diagnosis of investigated patients.
Left-sided obstruction 29
Coarctation 19
Aortic stenosis 4
Subaortic stenosis 2
Right-sided obstruction 17
Fallot/Pulmonary Atresia after repair
with pulmonary artery stenosis or
conduit stenosis
10
Pulmonary valve stenosis 4
d-Transposition of the Great Arteries
after Switch Repair with pulmonary
artery stenosis
2
Midventricular stenosis after ventricular
septal defect repair
1
The objectives of the study were to determine the follow-
ing
(1) if there was an association between baseline NT-
proBNP levels and clinical status,
(2) if there was an association between changes in NT-
proBNP level and the hemodynamic and/or clinical
response to the intervention.
2. Patientsand Methods
2.1. Patients. The study was approved by the institutional
review board of the Heart Centre in Bad Oeynhausen, Ger-
many. Following informed consent, 42 consecutive patients
between 1 day and 17 years (median 6 years of age) were
prospectively enrolled into the study between February 2007
and June 2008. All patients who presented during the study
period with either a left- or right-sided obstructive cardiac
lesionthatrequiredtherapeuticinterventionthroughcardiac
catheterization or surgical correction were included. Patients
with elevated serum creatinine at presentation were excluded
to avoid elevated levels of low molecular weight proteins
as a confounding factor. Left-sided obstruction was seen
in 25 patients and right-sided obstruction was diagnosed
in 17 patients. Nine patients required surgical correction
and 33 patients underwent interventional dilatation or
stent implantation via therapeutic cardiac catheterization.
Patients’ characteristics are provided in Tables 1, 2,a n d4.
The infants included in the study typically required an
urgent therapeutic intervention, whereas older children were
scheduled electively. All indications were based on clinical
(arterialhypertension,pulselessness,failuretothrive,cardiac
and consecutive respiratory failure) and echocardiographic
criteria. We used the modiﬁed Ross score as introduced by
Laeer et al to assess patients up to14 years of age for signs
of heart failure (32pts) [10–12]; see Table 5. A score of
4 and more was considered abnormal. Patients older than
14 years were classiﬁed according to the New York Heart
Association functional class (10pts). We deﬁned haemo-
dynamic improvement after a procedure as diminution of
a gradient more than 15mm Hg and/or the improvement of
an abnormal Ross score of more than 2 score points.
2.2. Echocardiogram. A complete echocardiographic study
wasperformedpriort othepr oc edur eand6t o12weekslater .
2.3. Blood Sampling and Assays. A peripheral venous blood
sample was collected one day prior to the catheterization or
surgical intervention and six to twelve weeks after the proce-
dure during an outpatient visit. After centrifugation, plasma
samples were stored either at 8◦C for less than three days or
at −20◦ for no more than six months, when NT-proBNP
was measured by immunoassay in batch. The IMMULITE
2000 System (Diagnostic Products Corporation DPC, Los
Angeles, California) was used to measure NT-proBNP in
50 microlitres of heparinized plasma. The imprecision of
the assay was 2.8% (range 0.80% to 11%) in the low range
(53pg/mL, n = 169) and −2.75% (range 0.32% to −6.22%)
in the high range (350pg/mL, n = 169).
Paediatric reference intervals have previously been pub-
lished. There is considerable ontogeny of the reference
intervals, largely owing to maturation of renal function and
to the peripartum circulatory changes. In brief, values of
<3.000pg/mL for newborns, <200 pg/mL for infants aged
28 days to 1 year, 100pg/mL for children aged 1–10 years
and <50 pg/mL for adolescents and adults were considered
normal [13–17].
3.StatisticalAnalysis
Patient data were expressed in median and range and
when appropriate as mean +/-SD for descriptive statistics.
The nonparametric Wilcoxon’s matched pairs test was used
to compare the levels before and after intervention and
Spearman was used to provide the correlation. For all
parameters, a value of P<. 05 was considered statistically
signiﬁcant. The statistical package GraphPad Prism software
version 5.01 for Windows (GraphPad Software, San Diego,
CA, USA) was used for the statistical analysis.
4. Results
Median concentration of NT-proBNP of all patients prior
to intervention was 312pg/mL (range 10–263,000pg/mL).
After intervention, the concentration dropped to a median
of 156pg/mL (range 20–10,300pg/mL. Figure 1). The
change in NT-proBNP was more obvious in patients who
showed signiﬁcant haemodynamic improvement (delta P
> 15mmHg) after procedures (NT-proBNP 409 versus
145pg/mL), but this change was not statistically signiﬁcant.
There was a good correlation between NT-proBNP and the
change of the clinical condition of the patients (modiﬁed
Ross, Laeer et al., and NYHA) after the intervention: P =
.0001 Spearman’s r = 0.68 (see Figure 2). This correlation
could not be found in the patients (n = 6) who had no
signiﬁcant haemodynamic changes after their procedure
(P = .3S p e a r m a n ’ sr = 0.41, see Figure 3).International Journal of Pediatrics 3
Table 2: Patient characteristics, clinical and echocardiographic data in median with range.
Variable (unit) All patients
(n = 42)
Left stenosis
(n = 25)
Right stenosis
(n = 17)
Symptomatic∗
(n = 27)
Asymptomatic
(n = 15)
Median age: years (range) 4.8 (0–17) 3 (0–16) 6.5 (0–17) 4.4 (0–16) 11.3 (0–17)
Surgical versus catheterization
interventions: 9/33 7/18 2/15 8/19 1 /14
Median peak gradient before
intervention (mm Hg per
catheterization and/or ECHO
in pts scheduled for operation)
64 (10–120) 50 (20–125) 85 (10–120) 64 (20–120) 64 (10–125)
Median peak gradient after
intervention (mm Hg per
catheterization and/or ECHO
in patients scheduled for
operation)
10 (0–90) 0 (0–40) 36 (0–90) 10 (0–80) 20 (0–90)
Median NT-proBNP before
(pg/mL)
280
(10–263000)
263
(10–263000) 312 (48–978) 1570
(120–263.000) 125 (10–944)
Median NT-proBNP after
(pg/mL)
134
(10–34300)
117
(20–34300) 193 (69–490) 480 (20–34300) 115 (20–490)
∗Symptomatic:increasedmodiﬁedRossScoreinpts0–14yorNYHAinpts>14yorarterialhypertensionanddiminishedpulsesinpatientswithcoarctation.
Table 3: Change of NT-proBNP concentrations (pg/mL) before and after intervention.
Hemodynamic
status
Number of
patients
NT-proBNP (pg/mL) (median and range) Peak gradient (mm Hg) (median and range)
Before After P Before After P
Unchanged 6 209 (10–460) 202 (20–338) ns 40 (10–100) 33 (10–90) ns
Improvement 35 409
(20–263.000)
145
(20–10.300) <.0001 64 (20–125) 10 (0–90) <.0001
Unchanged indicates patients with dP <15mmHg after procedure.
Table 4: Comparison of patients with left-sided obstruction and
right-sided obstruction.
Site of
obstruction
Number of patients NT-proBNP (pg/mL)
Left Side Total: 25
Neonates: 3 5437,11487 and 263.000
1–12 months: 7 204–13.779, median1570
1–10 years: 10 48–26430, median 108
Adolescents: 5 10–147, median 20
Right Side Total: 17
Neonates: 2 978 and 4290
1–12 months: 2 239 and 358
1–10 years: 6 224–944, median 445
Adolescents: 7 48–897, median 183
Although some children with left ventricular dysfunc-
tion had severely increased NT-proBNP concentrations, the
median value for NT-proBNP for left-sided lesions did not
diﬀer from right-sided obstruction (P = .5053, median of
patients with right-sided lesions 193pg/mL [n = 17], median
of patients with left-sided lesions 117pg/mL [n = 25]). The
characteristics of pts with left- and right-sided obstruction
are provided in Table 4.
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Figure 1: The evolution of the actual NT-proBNP values (log 10,
pg/mL) before and after intervention to treat a cardiac stenosis.
The diﬀerence between the values before and after intervention was
highly statistically signiﬁcant using Wilcoxon’s matched pairs test
(P<. 0001).
Theimprovementofthegradientofpatientswitharight-
sided cardiac stenosis was not as profound as in patients
with left-sided stenosis. The movements of the NT-proBNP
concentrations were summarized in Tables 2 and 3.4 International Journal of Pediatrics
Table 5: Clinical score modiﬁed from Ross and Reithmann et al. by Laeer et al.
Score (points)
01 2
History:
Diaphoresis Head only Head and body during exercise Head and body at rest
Tachypnea Rare Several times Frequent
Physical examination:
Breathing normal Retractions Dyspnea
Respiratory rate (respirations/min)
0–1y <50 50–60 >60
1–6y <35 35–45 >45
7–10y <25 25–35 >35
11–14y <18 18–28 >28
Heart rate (beats/min)
0–1y <160 160–170 >170
1–6y <105 105–115 >115
7–10y <90 90–100 >100
11–14y <80 80–90 >90
Hepatomegaly
(liver edge from right costal margin) <2cm 2–3cm >3cm
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Figure 2: Correlation between change in clinical status and NT-
proBNP (log 10, pg/mL).
Six patients with isolated coarctation required interven-
tion for arterial hypertension; otherwise they were asymp-
t o m a t i c .T h e i rN T - p r o B N Pw a sn o r m a la te n r o l m e n ta n d
remained unchanged after the procedure.
The patient with a worsening condition demonstrated a
parallel rise of NT-proBNP. This patient developed severe
pulmonary insuﬃciency after a surgical procedure, relieving
the pulmonary stenosis with a transanular patch. The NT-
proBNP level of this patient raised further to 23.100pg/mL
before he subsequently died.
5. Discussion
NT-proBNP is well established in adults for clinical manage-
mentofheartfailure.Itisapromisingmarkerformonitoring
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Figure 3: Clinical status and NT-proBNP (log 10, pg/mL) in
patients without change after the intervention.
cardiac impairment in children. This has been shown for
paediatric patients by Law et al. amongst others [5]. They
measured natriuretic hormone levels in pts with known
cardiac disease and could demonstrate that the patients with
ventricular dysfunction had signiﬁcantly higher levels. Price
and his group demonstrated that the natriuretic hormones
were a good predictor of adverse cardiovascular events
in paediatric outpatients with left ventricular dysfunction
[3].
Our study provides new insight on the impact of a
successful intervention for cardiovascular malformations on
NT-proBNPlevelsseveralmonthsafteraprocedure.Thedata
suggest that NT-proBNP could be an additional tool for the
indication of an intervention as well as a marker to follow
patients longitudinally.International Journal of Pediatrics 5
Several studies have been published that examined
short-term changes of NT-proBNP after a procedure. They
conﬁrmedtheperioperativeprognosticvalueofNT-proBNP.
Gessler and his colleagues could demonstrate that a high
preoperative NT-proBNP level was associated with a com-
plicated postoperative outcome [18]. Walsh and his group
found in their study that the NT-proBNP level measured
preoperatively in 38 children was a signiﬁcant predictor for
the length of stay on the intensive care unit after surgery and
that the peak postoperative level was a signiﬁcant predictor
oftheintensityoftheoverallmedicalmanagement[19].Shih
et al. supported the value of NT-proBNP as a postoperative
marker [20]. They examined 51 patients after congenital
heart surgery and found an association between duration of
ventilation and a NT-proBNP level > 540pg/mL with very
good sensitivity and speciﬁty. Koch et al. demonstrated in
their study that the natriuretic hormones initially increase
after cardiac surgery despite haemodynamic unloading and
speculated that this could be explained by a cytoprotective
role of the natriuretic hormones after surgery [21].
We used reference values that were composed from a
varietyofarticles[13–17]thatpublishedpreviouslycollected
NT-proBNP data in healthy children. It appears that widely
accepted age-dependent reference values have yet to be
established, but many authors based their clinical studies
on the reference data we used. It is reassuring that we
found high and clearly abnormal values only in very sick
children with signiﬁcant pathology and abnormal modiﬁed
Ross Scores. Sequential values appear to be of greater value
than a single measurement. This was also shown for cardiac
transplant patients—the change of NT-proBNP over time
correlated with their wellbeing, not the absolute value [22,
23]. The baseline value may be of prognostic signiﬁcance.
Patients with right-sided residual lesions may often be
clinically well. An elevation of NT-proBNP unexplained by
echocardiographic ﬁndings may point to the need for an
additional diagnostic workup, including MRI and/or cardiac
catheterization. In particular, peripheral pulmonary artery
stenosis with or without unequal perfusion of both lungs
can be missed by an echocardiographic study and can only
be assessed accurately by other diagnostic means. Khositseth
et al. support these ﬁndings in their study. They examined
twenty-one patients after Fallot repair with pulmonary
regurgitation. They reported that an NT-proBNP cutoﬀ
value of 115pg/mL can be used as a marker for detection of
right ventricular dilation and dysfunction [24].
The general picture that a successful intervention corre-
lates with a substantial reduction of NT-proBNP values did
not apply to a few adolescents with isolated coarctation who
had a normal NT-proBNP to start with. Their indication
for an intervention was related to arterial hypertension
rather than any element of cardiac compromise. Studies
in adults with aortic stenosis made similar observations.
In patients with preserved function of the left ventricle
despite a signiﬁcant pressure gradient, NT-proBNP was in
a normal range. The authors postulated that therapeutic
intervention might only be indicated in adult patients
with aortic stenosis with elevated NT-proBNP levels [1, 2].
We conclude that elevated NT-proBNP measurements in
patients with coarctation implied more severe disease with
signs of compromised systemic perfusion and failing left
ventricle as these patients had an elevated modiﬁed Ross
Score.
There is currently some controversy whether obesity may
inﬂuence NT-proBNP levels although one recent study has
called this into question [25]. Of note, none of our patients
had a BMI above the 95th percentile for age (data not
shown).
5.1. Limitations. Despite these promising ﬁndings, our study
has a few limitations. Kidney function was not speciﬁcally
determined, but all patients had normal serum creatinine
values (data not shown). Despite the possible accumulation
of small molecular weight proteins in chronic kidney disease,
newer data in adults suggest that NT-proBNP is helpful in
determining signiﬁcant cardiac illness in adults unless renal
function is severely impaired [26, 27].
The entire study group is small and not very homoge-
neous in terms of age, disease severity, type of lesion, and
type of intervention.
The patients with left-sided lesions seemed to have
similar NT-proBNP levels at the ﬁrst glance compared to the
patients with the right-sided lesions, but the patient group
with left-sided obstruction has been very inhomogeneous as
has been shown in Table 4.
6. Conclusion
NT-proBNP is a valuable additional tool to assess the
severity of a cardiac illness in children. A decline in NT-
proBNP appears to be a marker for successful intervention.
Similarly, a normal NT-proBNP may suggest room to delay
an intervention in the absence of clinical symptoms.
7. Summary
In adults, NT-proBNP is an important biomarker for
monitoring the severity of cardiac disease and its thera-
peutic response. In children, data remain limited due to
smaller numbers and inhomogeneous groups of patients. We
therefore studied NT-proBNP in 42 children with stenotic
cardiaclesionsbeforeandaftertherapeuticintervention.NT-
proBNP values were correlated with the clinical presentation
and echocardiographic data. NT-proBNP correlated well
with the success of the procedure and may help with the
monitoring of therapeutic interventions.
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